Late Response to Anti-CGRP Monoclonal Antibodies in Migraine: A Multicenter, Prospective, Observational Study.

Published in: Neurology (2023)

. Efficacy of anti-CGRP mAbs should be assessed at 24 weeks while treatment duration should be extended beyond 12 months.

Keyphrases